Hattangadi named President, COO of Spirox

Spirox Inc, which is backed by KKR, said May 16 that it named Neil Hattangadi, M.D., as its president and chief operating officer. Dr. Hattangadi most recently served as Business Leader, Peripheral Vascular at Royal Philips.


MENLO PARK, Calif., May 16, 2016 /PRNewswire/ — Spirox, Inc., a privately held medical device company, announced today the appointment of Neil Hattangadi, M.D., as president and chief operating officer. The new appointment follows the company’s recent $45 million Series C financing led by private equity firm KKR. Dr. Hattangadi brings to Spirox significant global medical device experience, having most recently served as Business Leader, Peripheral Vascular at Royal Philips. In this role, he will be responsible for all day-to-day operations of the company.

“We are excited to have attracted a proven medical device executive in Neil to help Spirox achieve our growth aspirations,” said CEO Duke Rohlen. “He brings deep capabilities in clinical development and commercialization, and strong leadership experience, which will be invaluable to Spirox as we bring cutting-edge innovations to market to provide breathing relief for millions of patients.”

“Spirox has developed a highly elegant approach to helping ENT physicians treat nasal airway obstruction,” said Dr. Hattangadi. “I am very excited by the promise of this technology, and I look forward to working with a world-class management team, investors, and scientific advisors to advance Spirox as a leading ENT company.”

Dr. Hattangadi served as Executive Vice President and General Manager of Peripheral Vascular and Global Clinical Affairs at Volcano Corporation. He grew the Peripheral Vascular group from inception to over $100 million in global sales, and was part of the Executive team that sold Volcano to Royal Philips for $1.2 billion in 2015. Previously, he was a healthcare investor at hedge funds including SAC Capital and Citadel Asset Management. Dr. Hattangadi was an executive at FoxHollow Technologies and ev3, Inc., and served as a consultant at McKinsey & Company. He earned a B.S.E. from Duke University, an M.Sc. from Oxford University as a Rhodes Scholar, and an M.D. from Harvard Medical School.


Spirox is a Menlo Park, CA-based medical device company that is focused on developing minimally invasive technologies that improve the quality of life for patients with nasal obstruction. For more information, please visit www.spiroxmed.com.


SOURCE Spirox, Inc.